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ABSTRACT
Thousands of transcriptome data sets are available,
but approaches for their use in dynamic cell re-
sponse modelling are few, especially for processes
affected simultaneously by two orthogonal influenc-
ing variables. We approached this problem for neu-
roepithelial development of human pluripotent stem
cells (differentiation variable), in the presence or
absence of valproic acid (signaling variable). Us-
ing few basic assumptions (sequential differentiation
states of cells; discrete on/off states for individual
genes in these states), and time-resolved transcrip-
tome data, a comprehensive model of spontaneous
and perturbed gene expression dynamics was de-
veloped. The model made reliable predictions (aver-
age correlation of 0.85 between predicted and sub-
sequently tested expression values). Even regula-
tions predicted to be non-monotonic were success-
fully validated by PCR in new sets of experiments.
Transient patterns of gene regulation were identified
from model predictions. They pointed towards acti-
vation of Wnt signaling as a candidate pathway lead-
ing to a redirection of differentiation away from neu-
roepithelial cells towards neural crest. Intervention
experiments, using a Wnt/beta-catenin antagonist,
led to a phenotypic rescue of this disturbed differ-
entiation. Thus, our broadly applicable model allows
the analysis of transcriptome changes in complex
time/perturbation matrices.
INTRODUCTION
Early cell fate commitment towards the neural lineage is
accompanied by highly dynamic and large-scale transcrip-
tome changes (1–6). Disturbances during this process can
alter developmental trajectories permanently. Accordingly,
key transcription factors as well as large transcriptome
modules, such as gene ontologies and constituents of reg-
ulatory circuits, are strongly affected (7–12).
Pluripotent stem cells (PSC) are good models to mimic
the in vivo processes during neurodevelopment. Human em-
bryonic stem cells (hESC) or induced pluripotent stem cells
(iPSC) are of particular interest, as this allows experimen-
tal access to the development of neuroectodermal and later
nervous system structures in man. Such neurodevelopmen-
tal processes have many species specific features (13–16) and
they could hardly be studied in a systematic way prior to the
advent of stem cell technology. Examples for human specific
aspects of brain development range from transposon activ-
ity (17), to largely differing time scales and relative steps of
wave-like gene activation patterns (18–21).
Prior to the classical neurodevelopmental stages, lead-
ing from neural stem cells to brain tissue formation and re-
gional specialization (16,22), early differentiation processes
lead from initially pluripotent cells to neuroepithelial pro-
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genitor cells (NEP) and various types of neural stem cells
(23). Such steps occur in fetuses during the formation and
initial folding/closure of the neural plate (24,25). In vitro,
the NEP cells form neural rosettes, a correlate of the neural
tube (26). A highly standardized method (STOP-tox(UKN)
assay) has been developed to track early neural develop-
ment and its disturbances via analysis of transcriptome
changes, epigenome alterations and the capacity to self-
organize in rosettes (8,9,12,23,27–29).
Disturbances of the regulatory networks that control
the spatio-temporal expression of genes can lead to se-
vere congenital malformations (e.g. spina bifida, anen-
cephaly) (30,31), and they may contribute to neuropsy-
chiatric disorders such as attention deficit/hyperactivity
disorder (ADHD), autism spectrum disorders (ASD) or
schizophrenia (32,33). Such disturbances can be induced
by genetics (34), stress experiences during fetal and early
childhood development (35) and environmental influences
(drugs, environmental and industrial chemicals, malnutri-
tion) (33,34). Little is known about the biochemical mech-
anisms that underlie these neurodevelopmental disorders,
and how and when transient perturbations, such as by
drugs, alter differentiation in a pathological way.
Valproic acid (VPA) may be used to establish bona fide
models of clinically-relevant neurodevelopmental disorders.
It is an anticonvulsant drug that is administered in epilepsy
and mood disorders and it is well known to increase the risk
for congenital malformation such as neural tube closure de-
fects and craniofacial malformations (30,31,36–38). Exten-
sive clinical data exist on VPA’s developmental neurotoxi-
city effects (39), and the relevant plasma concentrations in
fetal and maternal blood are known (40,41).
The impact of developmental disturbances depends
strongly on the time of onset and duration of the distur-
bance. In this sense, thalidomide (best known under the
brand name Contergan) gained notoriety as there were very
small time windows of in utero exposure identified that de-
termined the kind of malformation (42). Therefore, in or-
der to investigate the molecular mechanisms of such distur-
bances by using differentiating human PSC, it is important
to get a better understanding of how these perturbations
propagate to dysregulated gene activities and cellular phe-
notypes.
Mathematical models have been very instrumental to dis-
entangle the complexity of regulatory networks in general,
and of gene regulation in the context of stem cell differen-
tiation more specifically. Models have been applied to ana-
lyze networks on multiple layers. For stem cells, most mod-
els focused on the network of key regulators and the long-
term dynamics of cell fate decisions (43,44). Those models
were able to disentangle the network topology of small net-
works of key pluripotency factors and have helped to define
the logic that governs the stability and exit from pluripo-
tency or other cell identity transitions (45–47). Such de-
tailed mechanistic models build on extensive mechanistic
knowledge and often integrate detailed data from different
sources and studies. In contrast, a number of data-driven
modeling approaches have been used to model transcrip-
tome changes on a genome-wide scale. Broadly, these mod-
els were either used to infer quantitative information about
mRNA processing and turnover to describe the response of
the transcriptome to acute stimulations, or they have been
used to infer hidden variables like transcription factor activ-
ity from transcriptome time series data (48–52). So far, these
models were only applicable to describe the transcriptome
dynamics to immediate stimuli or the effect of individual
transcription factor on gene expression. Neither detailed
mechanistic approaches nor the current transcriptome-wide
modeling approaches are optimally suited to disentangle
the transcriptome dynamics of a differentiation program,
such as the transition from pluripotency to neural progen-
itor cells. As these transitions occur in a cascade of steps
and lead to waves of gene expression, models are needed
that consider the dynamic changes under control conditions
to evaluate modulations by stressors/toxicants. Moreover,
they need to be simple enough to be parameterized from
sparse data, such as transcriptome time series. We therefore
developed a coherent modeling framework that allows us
to describe and model transcript dynamics during differ-
entiation and to disentangle the effects of perturbation on
the transcriptome dynamics. Our model allows to describe
time-dependent gene expression in differentiating cells, and
it is sufficiently coarse-grained to be applied transcriptome-
wide. Using this model, we analyze differences between un-
treated and disturbed differentiation, where we study the
influence of VPA on transcript dynamics as an example.
We show that our kinetic model correctly predicts gene ex-
pression kinetics at concentrations of VPA not used for
training. Additionally, the model provides a mechanistic
basis to explain experimentally observed non-monotonic
concentration-response relations that were non-intuitive at
first. Finally, the model allows us to identify perturbed regu-
latory modules with high resolution in the time/compound
concentration space. With this approach, we find that treat-
ment with VPA leads to a transient upregulation of Wnt sig-
naling which in turn causes the upregulation of neural crest
genes. Our work shows that genome-wide models of tran-
scriptome dynamics during stem cell differentiation may
not only help to understand organogenesis/embryogenesis,
but will also shed new light on developmental disturbances
due to genetic and environmental stressors.
MATERIALS AND METHODS
Materials
Gelatine, putrescine, sodium selenite, progesterone, apo-
transferrin, glucose, insulin, ascorbic acid, valproic acid
and ICRT3 were obtained from Sigma (Steinheim, Ger-
many). Accutase was from PAA (Pasching, Austria). FGF-
2 (basic fibroblast growth factor), FGF-8b, Sonic hedge-
hog and noggin and were obtained from R&D Systems
(Minneapolis, MN, USA). Y-27632, SB-43154, CHIR99021
and dorsomorphin dihydrochloride were from Tocris Bio-
science (Bristol, UK). MatrigelTM was from BD Bio-
sciences (Massachusetts, USA). All cell culture reagents
were from Gibco/Invitrogen (Darmstadt, Germany) unless
otherwise specified.
Neuroepithelial and rosette differentiation
Human embryonic stem cells (hESC) (H9 from WiCells,
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protocol published by Chambers and colleagues (24) with
modifications established in (8,25). Instead of using 500 M
noggin we used the combination of 35 M noggin and 600
nM dorsomorphin together with 10 M SB-431642 for dual
SMAD inhibition as described earlier. This was used to
prevent BMP and TGF- signaling, and thus to achieve a
highly selective neuroectodermal lineage commitment. For
handling details, see supplemental material as decribed by
Balmer et al. (8). Beginning on DoD4, KSR medium was
gradually replaced by N2 medium (DMEM/F12 medium
with 1% Glutamax, 0.1 mg/ml apotransferrin, 1.55 mg/ml
glucose, 25 g/ml insulin, 100 M putrescine, 30 nM se-
lenium and 20 nM progesterone), supplemented with the
same amounts of noggin, dorsomorphin and SB-431642 as
KSR. All differentiations were performed in six-well plates
containing 2 ml of medium per well. For some experiments,
cells were further differentiated until they formed neural
rosettes. In detail, cells were differentiated until DoD10 as
described above or in Chambers et al. (24). On DoD11, cells
were detached using Accutase, and seeded at a density of
150 000 cells/cm2 onto Matrigel-coated 96-well plates or
glass cover slips. Cells were grown in N2S medium supple-
mented with 20 ng/ml FGF2, 100 ng/ml FGF8, 20 ng/ml
sonic hedgehog, 20 M ascorbic acid and 10 M ROCK
inhibitor Y-27632. On DoD13 ROCK inhibitor was re-
moved. Cells were fixed for immune staining at DoD15 after
rosettes had formed (26).
Experimental exposure
Developing cells were treated from DoD0–DoD6 with dif-
ferent concentrations of valproic acid (0.025, 0.15, 0.35,
0.45, 0.55, 0.65, 0.8 and 1mM) or the Wnt activator
CHIR99021 (2 M). For rescue experiments with the -
catenin Inhibitor iCRT3 (Sigma) cells were (co)treated from
DoD2–DoD6.
Immunostaining
For immunostaining, cells were fixed on DoD6 or DoD15
in 4% paraformaldehyde and 2% sucrose prior to perme-
abilization in 0.3% Triton X-100 in PBS. After blocking in
PBS containing 5% bovine serum albumin and 0.1% Tween-
20 for 1 h, primary antibodies (Supplementary Figure S1)
were incubated for 1 h, at room temperature (RT). After
washing, secondary antibodies were applied for 45 min at
RT. DNA was stained with Hoechst H-33342, and cover
slips were mounted in FluorSaveTM reagent (Calbiochem,
Merck).
Rosette formation assay
Rosette formation assay was performed in 96 well plates.
Number of rosettes was assessed in six technical replicates
for control and three technical replicates for treatments.
The immune cytochemistry staining of golgi matrix pro-
tein (GM130), zona occludens 1 (ZO1) and the DNA with
Hoechst H-33342 was used to identify rosettes. ZO1 is lo-
cated in the centre of a rosette, surrounded by GM130. Im-
ages of the whole well were taken by Cellomcis (Thermo
Fisher Scientific) automated microscope. Using Konstanz
information miner software (KNIME) (53), rosettes were
detected and counted. The number of rosettes per well was
normalized to the total nuclear area. Data is always dis-
played relative to an untreated control (Described in detail
in (26)).
Sample preparation for microarray analysis and quantitative
PCR
Cells were lysed in Trizol reagent (Quiagen) at the indicated
time points. mRNA was isolated as advised by the manufac-
turers protocol and an aliquot of 1g reverse transcribed in
a reaction mix of 20 l (iScript, Biorad: the cDNA synthesis
kit works with high sensitivity in this range. Standard curve
r = 0.998, efficiency = 96.5%). The reaction mix was di-
luted 1:5 in water. Quantitative PCR was performed in 10 l
samples using EVAGreen SsoFastTM mix (5 l EVAGreen
mix, 3.6 l water, 0.4 l primer (final concentration: 200
nM), 1 l cDNA (0.01 g)) on a BioRad Light Cycler (Bio-
rad, Germany). For quantification, qPCR threshold cycles
were normalized to reference genes [tatabox binding protein
(TBP) and ribosomal protein L13 (RPL13A)] (Primer list:
Supplementary Figure S2A). Data was either displayed rel-
ative to expression in stem cells or cells treated with chem-
icals were then expressed relative to transcript levels of un-
treated control cells (which had been grown and differen-
tiated for the same amount of time). For this normaliza-
tion, the 2–C(T) method was used (54). Primer specificity
was assessed by agarose gel electrophoresis and melting
curves are provided (Supplementary Figure S2B). A stan-
dard curve was generated for each pair of primers and effi-
ciency was measured (Supplementary Figure S2 A and C).
Affymetrix chip-based DNA microarray analysis (Hu-
man Genome U133 plus 2.0 arrays) was performed exactly
as described earlier (12,55). Expression kinetics for unper-
turbed differentiation were measured in quadruplicates at
the following 12 time points: 0, 6, 10, 16, 24, 36, 48, 60, 72,
96, 120, 144 h. Expression kinetics at 0.6 mM VPA were
obtained in quadruplicates at the time points 72 and 144 h
and in duplicates at 24, 48 and 96 h. Transcriptomes at 144 h
were obtained for the window treatments with 0.6 mM VPA
as follows. For treatment from 24 to 72 h in triplicates, for
treatment from 24 to 9 6h in quadruplicates and for treat-
ment from 72h to 144h in triplicates. One sample for the
window treatment from 72 to 144 h had to be removed
because of apparent mislabeling. Concentration dependent
transcriptomes were obtained at 144 h in triplicates at eight
VPA concentrations (0.025, 0.15, 0.35, 0.45, 0.55, 0.65, 0.8
and 1 mM) and were published earlier (27).
Data preparation
Gene expression data was normalised using bioconductor
and rma as described in (12). For each condition, we com-
puted the mean expression of each gene. Empirical Bayesian
estimates of the standard deviations were computed using
the ebayes function in the R package limma for each condi-
tion separately. These estimates were subsequently divided
by the square root of the number of replicates for each con-
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Batch effect correction
As the untreated kinetics and the kinetics obtained from
cells treated with 0.6 mM VPA were obtained in different
batches (first and second batch), we performed batch effect
corrections. For this, we used untreated samples at the time
points 0, 72 and 144 h, where we computed the difference in
expression between batches for each gene at the three time
points. These differences were linearly interpolated to ob-
tain b(t), the time dependent batch correction. Finally, for
each gene and time point, expression in the VPA-treated ki-
netic samples was transformed according to
expr′(t) = expr(t) + b(t);
where expr(t) denotes the measured gene expression at time
point t and expr′(t) is the batch corrected gene expression.
Selection of regulated genes
First, genes present on the microarray were restricted to
protein coding genes using the Ensembl database (Ensembl
84 from March 2016) through the R package biomaRt.
To identify regulated genes, the variation of the replicates
of single time points was compared to the variation with
respect to time using the Hotelling T2 statistic obtained
with the mb.long function from the R package timecourse
(www.bioconductor.org). For a description of the Hotelling
T2 statistic see Tai and Speed (56). The four replicates for
each of the 12 time points of the untreated kinetic served as
input to mb.long. The 1500 genes with the top T2 statistic
were labeled as regulated.
Model and cost function
The dynamic model consists of a linear chain of n states with
transition rates gon and goff. The rate gon is the on-rate of
each state and the off-rate of its preceding state. Only the
final state n has a different off-rate, goff. This model can be
analytically solved (see supplemental text S1 for details) to
obtain the quantity Act(t,n,gon,goff), the fraction of cells in
the active state. To model gene expression kinetics, we also
introduce a time shift dt and the parameters A and B as the
expression in states 0. . .n − 1 and n, respectively. Then the
gene expression Ep is given by Ep(t, A, B, gon, goff, n, dt) =
A + B Act(t + dt, n, gon, goff). To prevent non-defined values
when computing the logarithm, 1 + Ep is used instead of Ep
in the cost function. This amounts to a redefinition of the
parameter A.
To model the dependency of the rates gon (VPA) and
goff (VPA) on VPA, we use Hill functions of the form
g(VPA,k,n) = g + (g’ −g)*VPAn/(VPAn + kn) for both rates.
The full model thus contains the additional parameters gon’,
goff’, k1, k2, n1 and n2.
For each gene and each condition i, we compute the mean
Em,i of the measured expression and the standard error of
the mean Si as well as Ep,i, the expression predicted by the
model for condition i. The cost function used for fitting the
parameters is obtained by summing (Em,i− Ep,i)2/Si2 over
all data points from the untreated and treated kinetic in-
dexed by i. For the concentration-response data at t = 144
h the sum (Fm,i − Fp,i)2/Si2 over all data points indexed by
i is computed. Here, Fm,i is the measured fold change with
respect to the time point 144 h in the untreated kinetic and
Fp,i is the predicted fold change with respect to the predicted
expression for time 144 h, untreated. The overall cost func-
tion is the sum of both contributions.
Parameter estimation
We estimated the parameters by optimizing the differ-
ence between data and model simulations weighted by the
standard-deviation (see above). Because of the sensitivity of
optimization results with respect to starting parameters, the
often shallow cost landscape and the influence of the details
of the optimization algorithm, optimization is performed in
three iterations. In the first iteration, the microarray data
with the original expression standard deviation computed
with the limma package is used. In the second and third
iteration, the standard deviation is corrected by a factor de-
termined from the residuals of the first iteration fits. The
first and second iteration each start with fitting only the
data from untreated cells and subsequently fitting the full
data set to improve convergence of the optimizer in the 12-
dimensional parameter space of the full model. The third
iteration employs different optimization algorithms to im-
prove on the fit determined in the second iteration. We used
the analytical solution computed for the model for all op-
timization algorithms and the analytical gradient function
for algorithms that make use of a gradient (see supplemen-
tal text S1 and S2 for details).
For all fits, optimization parameters are restricted to the
intervals 10−5 < gon’ < 10, 10−5 < goff’ < 10, 10−2 < k1 <2, 1
< n1 < 4, 10−2 < k2 < 2, 1 < n2 < 4, 1 < A < 6 × 104, 1 < B <
105, 10−5 < gon < 3, 10−5 < goff < 3, 1 < n < 20, 10−2 < dt
< 100. In the following we list the optimization algorithms
and starting values used for the different iterations.
First iteration, fit of parameters A, B, n, gon, goff, dt to un-
treated data: optimizer GenSA from the R package GenSA
with initial values A = min(e), B = max(e), gon = 0.1, goff
= 0.01, n = 1, dt = 0, where e is the vector of expression
values in linear units for the respective gene and optimizer
option max.time = 200. Second iteration, fit of all param-
eters to the full data set: optimizer L-BFGS-B from the R
package optim with 1000 sets of random starting parame-
ters and optimizer options fnscale = 1, factr = 1e7, maxit
= 1000. Random parameters are generated in the interval
(1/5·par,5·par), where par is the optimized parameter from
the untreated fits using the latin hypercube sampling imple-
mented in the function randomLHS from the package lhs.
The parameters gon’, goff ‘, k1, k2, n1 and n2 that are not de-
termined in the first iteration, are either randomly drawn
from the entire allowed interval (k1, k2, n1, n2) or drawn
from the interval determined by gon and goff, respectively
(gon’, goff ’).
Second iteration, fit of parameters A, B, n, gon, goff, dt to
untreated data with rescaled standard deviation: as in the
first iteration but with option max.time = 1000.
Second iteration, fit of all parameters to the full data set
with rescaled standard deviation: as in the first iteration
with 1000 sets of random start parameters but with options
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Third iteration, fit of all parameters to the full data set
with rescaled standard deviation: optimization algorithms
GenSA and L-BFGS-B as described above as well as LM
(package minpack.lm) and NMKB (package dfoptim) are
used with 100 random starting parameters. Random pa-
rameters are picked form the interval (0.999 par, 1.001 par).
Optimizer options are set as follows. GenSA: max.time =
200, L-BFGS-B: fnscale = 1e6, factr = 1e2, maxit = 2e4,
LM: ftol = 1e–25, ptol = 1e–16, gtol = 1e–15, maxiter =
2e4 and standard options for NMKB.
Finally, if a set of parameters yielding a better fit of the
model to the data was encountered for a gene during the
profile likelihood analysis (see below), then this set was
adopted.
Parameter identifiability
To analyse parameter identifiability, we performed profile
likelihood (PL) as described in Kreutz et al. (57). First, op-
timal parameter sets were reoptimized using the L-BFGS-
B method to ensure a local optimum as start of the PL
procedure. Parameters were increased and decreased start-
ing from the optimal value with a fixed step size until the
cost was increased by more than 95%-quantile of the  2-
distribution with one degree of freedom or until the upper
or lower parameter boundary was reached. The minimal
and maximal parameter values determined in this way yield
the 95% parameter confidence interval. Further details of
the PL procedure are described in the supplemental infor-
mation (supplemental text S3).
GSEA
GSEA was performed using the HTSAnalyzeR package
for R. As reference gene sets for the GSEA we used
gene sets from the MSigDB v6.0 (gsea-msigdb.org),
containing manually curated gene sets from path-
way databases as well as published experiments (all
curated sets, c2.all.v6.0.entrez.gmt and KEGG sets,
c2.cp.kegg.v6.0.entrez.gmt). For all curated sets and
KEGG sets, we used a minimum gene set overlap of 20
genes for computing significance. The FDR for each gene
set was computed from 10 000 permutations. The GSEA
exponent was set to 1.
Pathway gene sets. Gene sets for Figure 4C–F were
obtained as follows. Neural crest signature genes were
taken from the MSigDB (see above) gene set named
‘LEE NEURAL CREST STEM CELL UP’. TGFbeta
pathway genes were taken from the MSigDB gene set
named ‘KEGG TGF BETA SIGNALING PATHWAY’.
Wnt pathway target genes were obtained from (58)
through the GEO database (GSE45223). Robust estimates
of the standard deviation were derived using an error model
that was parameterised as follows. The empirical standard
deviation for each gene and time point was computed us-
ing replicates. The data was then divided into 15 equally
sized bins based on mean expression, and the average em-
pirical standard deviation was computed within each of the
15 bins. For bins with expression <10, the standard devia-
tion was set to the maximal value. The resulting values were
then interpolated using the R function loess with a span
of 0.75. Wnt induced genes were obtained using the fold
change between samples ‘WA09 embryonic stem cells, NC,
day 3’ and ‘WA09 embryonic stem cells, DSi, day 3’ with a z-
value threshold of 3.5. Wnt repressed genes were obtained
using the fold change between samples ‘WA09 embryonic
stem cells, DSi, day 3’ and ‘WA09 embryonic stem cells, NC,
day 3’ with a z-value threshold of 3.5. The z-value was de-
fined as mean expression divided by the loess interpolated
standard deviation.
Gene ordering in heatmaps
In order to sort genes by the time of peak expression, gene
expression values were interpolated to a resolution of 0.1 h
using the R function loess with a span of 0.8. Subsequently,
the time point of the maximum value of the interpolated
expression was determined for each gene.
UMAP
Dimensional reduction of the transcriptome data for the
1500 top regulated genes was performed using the umap R
package with parameters n neighbors = 4, n epochs = 4000
and random state = 798395.
RESULTS
Heterogeneity of gene regulation during early neural differ-
entiation
We used an in-vitro system where human pluripotent stem
cells (hPSC) are differentiated according to the double
SMAD inhibition neural induction protocol to analyze
gene expression dynamics. We first obtained transcriptome
profiles at twelve time points during the first six days of
differentiation. To trigger a defined developmental distur-
bance (8,9,12,59), we treated cells with 0.6 mM VPA and
obtained the transcriptome samples after 1, 2, 3, 4 and 6
days (Figure 1A). A 2D Uniform Manifold Approximation
and Projection (UMAP) representation was chosen to vi-
sualize transcriptome changes over time. The progressive
gene expression changes over time were clearly visualized by
this approach. Compared to the trajectory of unperturbed
cells, VPA-treated cells were clearly offset (Figure 1B). As
first overview of gene expression dynamics on the individual
gene level the 1500 top regulated transcripts were ordered
by the time of their peak expression. The gene expression
heatmap clearly showed that many genes had their highest
expression at the start or end of differentiation, but that also
a sizeable number peaked at intermediate times (n = 810)
(Figure 1C). The sequential peaking of groups of genes is
typical for a highly coordinated sequence of neurodevelop-
mental steps. It may be explained by waves of gene activa-
tion programs.
The observed pattern is also consistent with the sequen-
tial occurrence of cell states that express particular genes.
We observed that the timing of peak expression remained
broadly unaltered in VPA-treated cells, although a detailed
comparison of the patterns showed individual genes that
shifted their time course of expression (Figure 1C). To fol-
low up on the latter finding, we examined whether VPA-
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Figure 1. The effect of HDAC inhibition on gene expression kinetics in spontaneously differentiating hPSC. (A) Time-resolved transcriptome data was
obtained during the differentiation of hPSC from the pluripotent state to the neuroepithelial stage (DoD6), using an established double SMAD inhibition
protocol to direct cell fate. Data were obtained for 12 time points (between 0 and 144 h) during undisturbed differentiation (VPA = 0 mM, n = 4 inde-
pendent differentiations), and for five time points in the presence of 0.6 mM VPA (n = 2–4). (B) Presentation of dimensionality reduced (UMAP method)
transcriptome data (time series for the 1500 most strongly regulated genes during undisturbed differentiation) to probe differences between normal and
VPA-affected differentiation. Numbers indicate the time (in h) after initiation of differentiation. (C) Heatmap of gene expression (row-wise z-normalized)
over time for unperturbed differentiation (left) and cells treated with 0.6 mM VPA (right). Expression is shown for the 1500 most strongly regulated genes,
sorted by the time of peak expression. (D) The distribution of the time point of peaking is shown for a subset of the 1500 genes from C that have their
peak expression at a timepoint after day 0 or before day 6. Genes were grouped as strongly affected by VPA (red, n = 64) or little affected by VPA (blue, n
= 746). (E) Examples of expression kinetics for genes with different behavior in the case of undisturbed differentiation and differentiation in the presence
of VPA. Data are means ± standard deviation. (F) Schematic of the structure of the kinetic model, based on the assumption that differentiation proceeds
via a sequence of discrete cellular states (e.g. stages 1–4), and that the speed of transition can be described by the transition rates gon and goff. A gene is
assumed to be expressed only in a single cellular state (here in state 4, red). For a given gene all transition rates between cell states are assumed to be the
same (gon).The decay rate of the final state (here: state 4) can differ (goff). Variations of gon/goff are exemplified in a 4-state model. The fraction of cells in
a given state is shown as a function of time. The model assumes all cells to be in state 1 at t = 0. The fraction of cells expressing the gene of interest (being
in state 4) increases with time. The two panels on the right show the effects of increasing either gon (top) or goff (bottom).
not significantly affected by VPA. However, transcripts
most strongly affected by the drug (log fold changes > 2)
showed a peak time distribution that did not differ from
little-affected genes (Figure 1D). This suggests that VPA
does not selectively affect genes induced at a specific time
point in development. The above analysis of the overall ex-
pression pattern showed that VPA-affected genes are not
peaking at a particular point in time and that the number
of genes peaking at a given time is not affected by the drug.
However, for individual genes we noticed that VPA treat-
ment can cause dramatic changes in the expression concern-
ing the timing as well as the extent of regulations (Figure
1E). The complexity of the transcriptome modulation by
VPA treatment was our incentive to develop a mathemati-
cal model of gene expression dynamics that would reflect the
observed expression changes over time. Our model assumes
that each cell transits through different states during differ-
entiation, and that each gene is expressed only in one spe-
cific state (Figure 1F). Application of the model to cell pop-
ulation averages implies that the gene expression data it pre-
dicts are determined by how many cells are in a state where
the gene is in the ‘switched-on’ state. To make the model
mathematically tractable, we based it on three assumptions.
(i) For each gene, the cell has to transit through n prior states
before it enters the state n + 1 where the gene is activated.
(ii) Cells transit through the first n states with a rate gon, and
they leave the active state with a rate goff. (iii) For each gene,
the parameters n, gon and goff can be different, i.e. each gene
is modeled separately (Figure 1F). The basic working of the
model may be exemplified for an n = 3 situation, in which
the gene of interest is expressed in state 4 (final state) (Fig-
ure 1F, bottom, left). On the population level, an increase of
gon in this situation would lead to earlier and more peaked
gene expression (Figure 1F, top, right). An increase of goff
would lead to an overall attenuated expression (Figure 1F,
bottom, right). An intuitive explanation for this is that few
cells ever occupy state 4 at the same time, because the off-
rate goff is high compared to the on-rate gon. To allow the
model to fit also genes that decrease monotically in expres-
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Figure 2. Establishment of a mathematical gene expression model of VPA-disturbed neurogenesis. (A) Data matrix used to fit the combined kinetic and
VPA effect model. For each condition marked in black, data from two to four microarrays were used. All numbers refer to independent differentiations.
(B) Curves exemplifying various types of concentration-response behavior of individual genes (means ± standard deviation, n = 3). Data for the effect of
eight VPA concentrations on day 6 (t = 144 h) are shown. (C) Exemplification of the VPA effect model constraints (for goff and an example gene down-
regulated by VPA): It is assumed that the two rate constants of the kinetic model (gon and goff) depend on the concentration of VPA, and can be described
by a Hill model (shown in the first column). The Hill function ‘goff (VPA)’ is parametrized in such a way that the multi-step model fits both the endpoint
data (expression levels for different VPA concentrations measured at 144 h, column 2) and the kinetic data (measurements of gene expression at different
times ≤ 144 h, column 3). Three examples illustrate how the combination of constraints by endpoint and kinetic data lead to model optimization for goff
(VPA). Upper panel: the kinetics are correctly fitted but the endpoint is wrong for small concentrations because the Hill curve is not steep enough. Middle
panel: both the endpoint and kinetic data (after VPA treatment) are not correctly fitted because the turning point of the Hill function is at too high VPA
concentrations. Bottom panel: correct function goff (VPA), fitting both the endpoint and the kinetic data. (D) Example fits for the genes PAX6 (top) and
LGI1 (bottom). The left two panels show the fits for the Hill model, with the blue and brown points indicating the VPA concentrations of 0 and 0.6 mM,
respectively. The third panel shows data and fit for the gene expression kinetics in the absence (blue) or presence of VPA (0.6 mM, brown). The fourth
panel shows the data for the 9 VPA concentrations and one untreated sample at the endpoint (144 h) of the differentiation together with the fit line from
the model. (E) Amplitude shift and time shift with respect to fitted gene expression kinetics are indicated by the offset of brown and blue dotted lines. (F)
Distribution of genes with respect to the amplitude shift triggered by 0.6 mM VPA compared to the untreated differentiation. (G) MA-plot for the change
in peak time triggered by 0.6 mM VPA compared to the untreated differentiation. For each gene that peaks after day 0 or before day 6, the change in peak
time is plotted against the mean of the peak time in the treated and untreated conditions. The red line indicates a loess interpolation with span 0.75.
This parameter shifts the peak to the left so that the data
can exclusively be fitted to the decreasing flank of the peak.
Modeling of dynamic transcriptome disturbances by VPA
In order to extend the model to VPA-treated cells, addi-
tional data were required. We used transcriptome data pub-
lished earlier (28), in which the effect of eight additional
VPA concentrations (from 25 M to 1 mM) was measured
after 6 days of differentiation (Figure 2A). When we in-
spected concentration-response curves for different genes
in this data set, we noticed a high heterogeneity: for exam-
ple gene expression was perturbed at different VPA concen-
tration thresholds (NEFL is very sensitive while HPGD is
only perturbed at high concentrations of VPA). Also, we
found the deregulation to reach a saturation (SIX3) or not
(KLF5). Finally, we noticed that some genes showed a non-
monotonic concentration-response (e.g. GAD1 or NR2F2)
(Figure 2B).
In order to set up a model for the VPA effect that reflects
the molecular features of the neurodevelopmental program,
we reasoned that VPA was unlikely to affect the number of
cell states. We assumed the drug to alter the parameters gon
and goff. Therefore, we made gon and goff monotonic func-
tions of the VPA concentration (modelled using a Hill func-
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Figure 3. Multi-state model-based predictions of gene expression under the influence of VPA. (A) Model fit and experimental validation for genes with
different types of concentration-response behavior. The left panel shows examples of genes with largely monotonic concentration-response behavior. The
right panel exemplifies non-monotonic responses. For each gene, the first column (from left to right) shows the experimental data (means ± standard
deviation) together with the model fit for the time-dependent expression in the presence of 0 (blue) or 0.6 mM (brown) VPA. Next, the concentration-
response data for 6 days of VPA exposure are shown together with the model fit. The third column indicates the model predictions for gene expression
kinetics at VPA concentrations of 0, 0.35, 0.6 and 0.8 mM. The fourth column shows expression kinetics data from a validation experiment using RT-PCR
(means ± SD, n = 3). The concentrations were 0, 0.35, 0.6, 0.8 mM (blue to orange). (B, C) Detailed exemplification of non-monotonic concentration-
response behavior predicted by the model for the GAD1 gene. The graphs in B show how the VPA concentration affects the production rate (gon) and
the decay rate (goff). Both rates change monotonically with the VPA concentration. (C) The left plot shows the computed model prediction of gene
expression over time, at VPA concentrations increasing from blue to orange (range: 0–1 mM). The peak concentration not only increases with increasing
VPA concentration, but also moves to earlier time points. The plot to the right shows fold changes in gene expression based on the data on the left, for a
time of 72, 96 and 144 h and for various VPA concentrations versus control.
sion data at t = 144 h for different VPA concentrations and
(ii) to the time series data for unperturbed differentiation
and differentiations at 0.6 mM VPA (Figure 2C). This pro-
cedure was applied for each gene, i.e. training each model
with 12 parameters on data from 86 samples for 25 condi-
tions. Example fits are shown for the genes PAX6 and LGI1
(Figure 2D). The plots for the input functions for gon and
goff illustrate how different concentration dependencies of
the rates gon and goff can lead to distinct concentration-
response behavior at the endpoint. We found that the multi-
step model with VPA concentration-dependent rates cor-
rectly described the observed changes in gene expression
amplitude and timing caused by VPA treatment (Figure
2D).
To judge the general ability of the model to fit the ki-
netic and concentration-response data, we computed the
correlation between data and fits. We found a correlation
coefficient larger than 0.9 for 88% of the 1500 fitted genes
for the unperturbed differentiation. For the concentration-
response data, we compared the fits to the data for genes
with a minimum log2 fold change of 1 at the endpoint. For
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higher than 0.9. We concluded that the model correctly de-
scribes expression patterns for the large majority of regu-
lated genes in the presence and absence of VPA.
Since the model describes peaked gene expression kinet-
ics, parameter identifiability will in general depend on the
peak location. For montonically decreasing or increasing
genes, where the peak is outside of the observed time frame,
we expect gon and goff to be less identifiable than for genes
peaking at intermediate times. To analyse parameter iden-
tifiability, we performed a profile likelihood analysis which
allows to compute parameter confidence intervals (57), ex-
emplified for the gene POU4F1 in Supplementary Figure
S6. As expected, gon, goff, dt and n are best defined for genes
peaking at intermediate times (Supplementary Figure S7).
The considerable uncertainty in these parameters even for
genes with a clearly defined peak is also due to structural
non-identifiabilities. For instance, a shift in the peak loca-
tion to earlier times by increasing gon can be offset by in-
creasing n. Peak times, which are computed from a com-
bination of parameters, are better identifiable (Supplemen-
tary Figure S8). For genes peaking at intermediate times,
the uncertainty in the peak time is comparable to the time
resolution determined by the transcriptome samples.
In order to characterize the overall effect of VPA on regu-
lated genes, we computed the change in peak-to-trough ex-
pression (amplitude shift) and the change in peak timing
(time shift) (Figure 2E) from the model fits. We observed
a bias towards a decreased amplitude upon VPA treatment
(68% of all regulated genes) (Figure 2F). This bias was re-
tained when restricting the analysis to genes with a sig-
nificant change in amplitude (Supplementary Figure S9).
When plotting the change in peak timing against the av-
erage of the peak time in the untreated and VPA-treated
conditions, we noticed an average peak time shift towards
later times for genes that peak intermediately (Figure 2G).
When restricting the analysis to genes with a significant
peak time shift, the average delay became more pronounced
(Supplementary Figure S10). The model fits thus indicate
that expression changes over time are mostly attenuated and
delayed by VPA. Taken together, we established computa-
tional models for hundreds of genes that capture gene ex-
pression kinetics during differentiation and model the in-
fluence of VPA on the kinetics.
Explanation of non-monotonic concentration-response curves
by the gene expression model.
We set out to validate the gene expression kinetics pre-
dicted by the model by generating additional kinetic data
at VPA concentrations that have not been used for model
fitting. Gene expression kinetics for 12 genes were mea-
sured at 0.35, 0.6 and 0.8 mM VPA using quantitative RT-
PCR. We selected these 12 genes to cover a broad range
of qualitatively different concentration-response curves
with respect to VPA at t = 144 h (Figure 3A). Satu-
rating concentration-responses were exemplified by three
genes (PAX6, DAZL, OTX2) that are down-regulated and
two genes (BMP5, SOX9) that are up-regulated by VPA.
POU4F1 was included as a gene that shows a slight increase
in expression at low concentrations, and a pronounced de-
crease at high concentrations. Most importantly, we also se-
lected genes that show a pronounced non-monotonic be-
havior, where expression is either reduced or increased at
intermediate, but not at high concentration (Figure 3A,
right column). Using the model fits, we simulated expression
kinetics for the three different VPA concentrations (0.35,
0.6 and 0.8 mM VPA). The model predicted that treat-
ment with VPA can dramatically alter the amplitude of peak
expression (see e.g. OTX2), as well as timing of peak ex-
pression (see e.g. DAZL). BMP5 exemplified the case of
changes in both peak expression and peak timing. When
comparing the peak timing and changes in amplitude ob-
served in the RT-PCR data, we observed good qualitative
agreement with the model predictions (Figure 3A, right-
most panel for each gene). Quantitatively, the 12 tested
genes have an average correlation between predicted and
measured expression values of 0.85 (Pearson’s r). Our obser-
vation that non-monotonic concentration-response curves
were predicted with high accuracy was surprising, given
the fact that the model represents the effect of VPA as
monotonic functions (gon(VPA) and goff(VPA)). We there-
fore analyzed the model simulations with regard to the
question how such behavior can occur. An intuitive under-
standing of this model feature can be obtained from a de-
tailed examination of the GAD1 gene (Figure 3B/C). In this
example, gon increases with increasing concentration and
goff decreases with increasing concentration. This leads to
an increase in amplitude and earlier peaking times as the
VPA concentration is increased (Figure 3C). However, be-
cause goff is more sensitive to changes in concentration than
gon, the increase in amplitude precedes the change in tim-
ing. This explain why, at t = 144 h expression is first in-
creased, then decreased. We concluded that the gene ex-
pression model we developed correctly predicts differentia-
tion kinetics at VPA concentrations on which the model was
not trained. It furthermore helps to explain non-monotonic
concentration-response curves, as monotonic changes in ac-
tivation and de-activation kinetics can in combination lead
to non-monotonic fold change at a given timepoint (e.g. t
= 144 h), while peak time and maximal expression change
monotonically.
Identification of Wnt signaling as major driver for divergent
differentiation
Due to non-monotonic and transient effects of VPA, anal-
yses of single time points or at single concentrations might
be misleading. We therefore used our gene expression model
to predict gene expression for various times and VPA con-
centrations, and used these predictions to ask which cellu-
lar processes are perturbed by VPA during differentiation.
Specifically, we predicted fold changes for regulated genes
at densely spaced time points (0–144 h) and VPA concen-
trations (0–600 M). Subsequently, we performed gene set
enrichment analysis (GSEA) on the predicted fold changes.
The term with the maximum enrichment score was ‘Neu-
ral Crest Stem Cell up (NCSC)’. For the VPA concentra-
tion of 0.6 mM, a concentration well within the therapeutic
range of VPA as an anticonvulsant drug (60,61), and associ-
ated with clinical birth defects (28,60–63), neural crest stem
cell (NCSC) signature genes were enriched from about 50
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Figure 4. Up-regulation of Wnt and TGFbeta pathway genes in cells exposed early in the differentiation time course to VPA. (A) GSEA using curated
gene sets from the MsigDB on the fold change between VPA-treated and untreated cells at the indicated time points and concentrations. The significance
of enrichment is shown as a heatmap for the top enriched term ‘Neural crest stem cell up’ (q < 10−4) The fold change data were measured for different
VPA concentrations at the time point 144 h and for different time points at the concentration of 0.6 mM VPA (grey indicates no measurement available).
Fold changes for all other times and concentrations are model predictions. (B) GSEA as in A using KEGG pathway gene sets available in the MsigDB. The
enrichment scores are shown as heatmaps for the three top enriched pathways (q < 0.05), with red indicating enrichment and blue indicating de-richment
(grey indicates no measurement available). (C) The fold change between cells treated with 0.6 mM VPA and untreated cells is shown as a heatmap for
Wnt-induced and Wnt-repressed genes separately at the indicated time points. Significance is indicated below the time point (*P < 0.05, Fisher’s test) (D)
The average fold change between cells treated with 0.6 mM VPA and untreated cells is shown for the following groups of genes: Genes up-regulated in
neural crest cells (Neural crest), genes induced by Wnt signaling (Wnt) and genes annotated as being part of the TGFbeta pathway (TGFb). The symbols
indicate the significance of the up-regulation at the respective time point (*P < 0.05; **P < 0.01; ***P < 0.001, Wilcoxon rank sum test) (E) Average
concentration-response curves at the differentiation endpoint (t = 144 h) for gene groups from D are shown. The symbols indicate significance as in (D).
(F) H9-hPSC were differentiated towards neuroepithelial cells and treated with 0.6 mM VPA during different time windows. Two early windows, 24–72 h
(blue) and 24 h-96 h (green) as well as two late windows, 72–144 h (magenta) and 96–144 h (orange) were compared to the continuous treatment 0–144
h (red). GSEA on the fold change of VPA treated cells compared to untreated cells for neural crest up-regulated genes for different treatment windows:
Coloured lines indicate the enrichment score for the respective treatment window and coloured vertical bars indicate the fold change rank of all neural
crest up-regulated genes with respect to the fold change of all genes for the respective treatment window.
to 0.1 mM), enrichment was found, but it occurred at later
time points (Figure 4A).
The model predictions were further used to identify pos-
sible mechanisms by which VPA induces NCSC genes. We
found only 7 KEGG pathways showing a sufficient overlap
with our set of regulated genes to compute meaningful p-
values. Three of them were significantly enriched: neuroac-
tive ligand receptor interaction, MAPK signaling and Wnt
signaling. The time-concentration matrix of the enrichment
scores of neuroactive ligand receptor interaction indicated
activation of this pathway at minimal VPA concentrations,
and increasing the concentration did not enhance this effect.
For MAPK signaling, 300 M VPA led to an up-regulation,
which persisted until at least 144 h. The regulation of Wnt-
associated genes was particularly interesting, with only a
transient up-regulation that ended between 100 and 120 h.
Increased VPA concentrations shifted the time frame of up-
regulation towards earlier times, so that it was not enriched
for at the 144 h data points (Figure 4B).
The predicted up-regulation of Wnt signaling is remark-
able, because together with TGF signaling, it is known to
play a role in neural crest development (64,65). To further
investigate the connection between Wnt/TGF signaling
and NCSC induction, we derived a Wnt target gene signa-
ture (Supplemental Table S1) from a transcriptome study
in human embryonic stem cells (58). When examining the
VPA-induced fold changes for these genes at the relevant
time period (48–96 h), we observed that Wnt induced genes
tended to be up-regulated by VPA, while Wnt-repressed
genes were rather down-regulated. Additionally, the major-
ity of TGF pathway genes were upregulated by VPA (Sup-
plementary Figure S11). This trend is consistent with an ac-
tivation of Wnt signaling by VPA (Figure 4C).
To confirm this activation hypothesis, we used a more ro-
bust approach: average fold-changes caused by VPA treat-
ment for Wnt-activated genes, for TGF pathway genes,
and NCSC signature genes were calculated for measured
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Figure 5. Interference with toxicant-induced Wnt activation and neural crest formation. (A) Pluripotent stem cells were differentiated within 6 days to
neuroectodermal precursor cells; in some experiments, these were further differentiated until DoD15, when they formed neural rosettes. The developing cells
were either exposed to valproic acid (VPA; 400 M; from DoD0–DoD6) or they were co-treated with VPA + ICRT3 (beta-catenin inhibitor; 30/60 M; from
DoD2-6). For analysis, gene expression was measured by quantitative real-time PCR (qPCR), marker proteins were evaluated by immunocytochemistry
or rosette formation was quantified by immunostaining followed by automated imaging. (B) The mRNA levels of three neural crest marker genes (TFAP2,
PAX3, MSX1) was measured after treatment with VPA alone or VPA + ICRT3. Data is shown as fold change relative to the untreated control. (C) Cells
were fixed and immunostained for SOX10 and nestin, after treatment with VPA or VPA + ICRT3 (30 M). (D) Quantification of SOX10 staining in
DoD6 cells. Stained cultures were imaged and SOX10-positive pixel were counted. They were normalized to the nuclear area (H-33342-positive pixels). (E)
Cells were differentiated and treated as described in A until DoD15. Immunostaining was performed for ISL1 and p75, and quantification was performed
as in D. Data is shown relative to untreated controls. (F) Cells were treated as described in A until DoD15. Then, the tight junction marker ZO1 (zona
occludens 1; red), the golgi marker GM130 (Golgi matrix protein 130 kDa; green) and nuclei (blue, H-33342 DNA-intercalating dye) were stained, and
rosette formation was quantified. The left images show untreated cells that form neural rosettes. Each red dot surrounded by a green halo represents one
rosette. The two dashed white rings (80 m diameter) indicate exemplary rosettes. (G) The neural rosette formation assay (RoFA) software was used to
quantify rosettes (normalized to the number of cells in a well). Data are given relative to the untreated control. All data are means ± SD of at least three
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that VPA treatment indeed lead to a transient response for
Wnt-induced genes. In contrast, NCSC signature genes and
TGF pathway genes showed increased up-regulation over
time (Figure 4D).
Predictions from our model suggested that NCSC signa-
ture genes were induced already at very low VPA concentra-
tions (Figure 4E). A steep increase in regulation by VPA was
observed in the 200–400 M range, while the average fold
change hardly increased at concentrations above 0.5 mM.
Such data are of high interest for systems pharmacology
models and toxicity prediction algorithms. With respect to
our model, it was also very interesting to observe that Wnt
signaling target genes were not significantly altered, when
analyzed at the usual model endpoint (144 h) (Figure 4E).
They were only clearly identified by modeling of data for
earlier time points. This re-emphasizes the need to provide
and analyze kinetic data.
The transient activation of Wnt signaling targets could
mean that differentiating cells are susceptible to altered
Wnt signaling only for a limited duration. This would ex-
plain the frequent observation in developmental toxicol-
ogy of particular windows-of-sensitivity (9,26). To inves-
tigate this further, we treated cells with VPA at different
times and with variable treatment duration and reanalyzed
a published dataset (26,27) (Figure 4F). GSEA for NCSC
genes showed a marked difference between early and late
treatment windows, with late treatments failing to efficiently
upregulate NCSC genes. Brief early treatments led to a
very similar up-regulation as continuous treatment. This
implies that differentiation disturbances by VPA are most
efficient/toxic during early neurodevelopmental periods
(Figure 4F). Taken together, these applicability tests of our
mathematical gene expression model show that this form of
data analysis can unveil complex regulation patterns, exem-
plified here by a transient dysregulation in Wnt signaling
associated with a permanent up-regulation of the NCSC
fate.
Altered VPA-induced neural crest formation by interference
with Wnt signaling
Finally, we tested in how far the toxicant-induced shift
of differentiation from neuroepithelial cells towards neural
crest cells may be prevented by interference with Wnt signal-
ing. First, a diverse set of Wnt target genes relevant for early
neurodevelopment (DACT, SP5, SIX3, GAD) was analyzed
to compare the response to VPA with the one triggered by
the well-established Wnt activator CHIR (CHIR99021; a
specific inhibitor of glycogen synthase kinase-3) (9,66). The
analysis was performed after three days of differentiation
(DoD3), a time period relevant to fate switching. Both VPA
and CHIR triggered similar response patterns (Supplemen-
tary Figure S3A). Moreover, analysis of the established
neuroepithelial test endpoints (expression of PAX6 and of
OTX2) on DoD6 confirmed that Wnt activation during the
differentiation process by CHIR indeed disturbed the cor-
rect differentiation. The drug attenuated the up-regulation
of PAX6 and of OTX2; in other words, CHIR triggered
a relative downregulation of the neuroepithelial markers
compared to untreated control cells (Supplementary Figure
S3B).
Having established that Wnt signaling may disturb neu-
roepithelial differentiation in our experimental system, we
used the beta-catenin inhibitor ICRT3 as tool to attenuate
this pathway. In a proof-of-concept experiment we found
that ICRT3 attenuated the expression of typical neural crest
genes (TFAP2, PAX3, MSX1) in cells treated with CHIR
(Supplementary Figure S4A). Thus, we proceeded to a se-
ries of experiments investigating the effect of ICRT3 on
cells treated with VPA (Figure 5A). On the gene expres-
sion level, 30 M of ICRT3 already attenuated the VPA-
induced up-regulation of TFAP2 and MSX1, but not PAX3
(Figure 5B); at higher concentrations (60 M), ICRT3 had
pronounced attenuating effects on all three neural crest
marker genes (Supplementary Figure S4B). More impor-
tantly, the beta-catenin inhibitor also prevented protein ex-
pression of the neural crest master regulator SOX10 in the
presence of either 400 M (Figure 5C) or 600 M VPA
(Supplementary Figure S5A). This phenotypic effect was
persistent, as the intermittent treatment with ICRT3 (from
DoD2–DoD6) also prevented the up-regulation of neu-
ral crest marker proteins ISL1 and p75 (also named TN-
FRSF16, CD271, p75NTR) at DoD15 (Figure 5D, Sup-
plementary Figure S5B). These data strongly suggest that
the intermittent up-regulation of Wnt pathway genes con-
tributes to the differentiation switch away from neuroep-
ithelial cells and towards neural crest. The rescue from dis-
turbed neuro-differentiation by ICRT3 was further investi-
gated in a rosette formation assay (26,27). Self-organized
formation of rosettes is a hallmark of the neuroepithelial
phenotype, and has been considered as functional correlate
of neural tube formation (8,67). The cells generated by our
standard protocol (26) showed extensive formation of neu-
ral rosettes, which was completely disturbed in cells exposed
to VPA during the pivotal differentiation period of DoD0–
DoD6 (Figure 5F). Co-treatment with ICRT3 (from DoD2-
DoD6) fully restored the rosette formation capacity of the
cells (Figure 5F, G). Thus, interference with Wnt signaling
at a critical period of differentiation prevented the neurode-
velopmental phenotype triggered by VPA.
DISCUSSION
Analyzing perturbations of differentiating cells is particu-
larly difficult compared to similar approaches in more or
less static cell cultures. For instance, a matrix of time- and
concentration-resolved data needs to be analyzed. Here, we
used interpolation of a limited amount of data by a ki-
netic model to make such an analysis feasible. The mod-
eling principle may be applied to any other differentiation
process in cell biology and organism development that is
affected by an additional factor (signaling molecule, drug
or gene dose). Previous genome-wide modeling was mainly
focused on the description of gene expression dynamics in
terms of RNA production and turnover rates (e.g. (52)).
This allowed excellent modeling of transcriptome changes
triggered by defined signaling events in static cell cultures.
Extensions of these models allowed very precise predictions
of kinetic rates, particularly when combined with metabolic
labeling (68–70). Recent progress also allowed definition
of cell trajectories in single cell data (71). A major princi-
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scriptome descriptions is our model assumption of distinct
cellular states in which particular genes are expressed, and
that the transition between these states is slow relative to
gene expression kinetics. This feature allowed us to model
long time series as typically observed during differentiation
of human cells. An important finding of the model applica-
tions was that a small set of simple assumptions (e.g. mono-
tonic modeling of gon and goff) can lead to predictions of
complex behavior, such as non-monotonic concentration-
response curves. Another important conclusion is that few
experimental samples may be used to predict unobserved
points in a relatively large data matrix. Vice versa, the model
may be used in the future to predict the most efficient ex-
perimental design to allow robust predictions in particular
sub-areas of the differentiation-disturbance matrix.
With the help of model simulations, we studied the effect
of VPA on differentiating stem cells during the first six days
of a well-established neural induction protocol. This model
was chosen to exemplify processes where dynamic natural
transcriptome changes are overlaid with those triggered by
an external stimulus (2-dimensional response matrix). This
particular biological model was also used as it is supported
by robust clinical data (72,73). The use of VPA during preg-
nancy can lead to a complex phenotype, often described as
fetal valproate syndrome. Notably, different windows of ex-
posure need to be distinguished. If the drug is given during
the period of neural network formation (pregnancy months
2–3 onwards), an autism-related phenotype may arise. This
is associated with the endophenotype of altered neurite
connectivity, and it has recently been shown to be related
to the down-regulation of the cytoskeletal/microfilament
regulator MARCKSL1 (59). Drug exposure during earlier
phases of development (about 4 weeks after conception)
is better documented, and it leads to neural tube defects
and alterations related to neural crest function (e.g. cleft
palate) (72,73). Spina bifida and hydrocephalus are the clin-
ically best-documented malformations in this case, and the
test system used here (STOP-tox(UKN)) refers to this neuro-
teratological problem (8). Interestingly, the upstream sig-
naling disturbances triggered by VPA may be similar in
early and late phases: HDAC inhibition and block of GSK-
3 activity. The activation of the Wnt pathway, and a related
shift from central neural development to neural crest devel-
opment was found here as a main pathological pathway for
early-stage drug exposure.
In exposed rats, it was shown that VPA induced beta-
catenin and phospho-GSK3 in brain tissue (74,75). Al-
though such studies suggest that VPA treatment affects Wnt
signaling, an exact molecular explanation is still lacking.
VPA itself is a poor inhibitor of GSK3, and other molecules
that trigger similar responses as VPA (e.g. trichostatin A)
do not affect this kinase at all. Possibly, the main primary
target of VPA is a broad spectrum inhibition of HDACs
(excluding HDAC6), which then leads indirectly to a Wnt
response (40,76). It has been shown that the direct effects
of VPA on histone acetylation have an indirect, but perma-
nent effect on methylations (9). In line with this, it has been
suggested that VPA increases the expression of Wnt target
genes in prenatally exposed rats by altering demethylation
state of Wnt-activators (77). Dissecting the transcriptional
changes by which VPA affects Wnt signaling is complicated
by the dynamic nature of the problem. The initial signaling
phase is quickly followed by secondary effects, and signal-
ing pathways often contain feedbacks that limit signal dura-
tion. Thus, the timing of the observations after a perturba-
tion can be critical when trying to identify direct effects on
signaling, and concentration-dependent effects complicate
the analysis. Our approach tries to overcome these limita-
tions by augmenting the limited experimental resolution in
time–concentration space using a dynamic model.
Further insights could be gained in the future by com-
bining the model with single cell transcriptome data. This
would allow anchoring of the model states to transcrip-
tome states that are observed in cells during differentiation
(78–81). Under such conditions, we would be able to use
the same states and their transition rates for all genes, in-
stead of using independent state models for each gene. This
would further constrain the parameters and thus provide
robustness and interpretability of the model. Consequently,
the transition rate parameters could yield typical half lifes
of transcriptome states that are currently inaccessible by
models using a single cell snapshot. It would also comple-
ment pseudotime reconstruction algorithms that lack abso-
lute time scales (82,83).
Taken together, our modeling framework allowed us to
model the effect of a perturbation on a complex develop-
mental transition and helped us to unveil the molecular
pathway that mediates dysregulation due to the perturba-
tion. We believe that this framework is broadly applicable
to the analysis of transcriptome changes in complex differ-
entiation processes that are subjected to perturbations.
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